The stock has a 36-month beta value of 0.19. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 5 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for IONS is 155.28M, and at present, short sellers hold a 9.55% of that float. On June 12, 2025, the average trading volume of IONS was 1.65M shares.
IONS) stock’s latest price update
The stock of Ionis Pharmaceuticals Inc (NASDAQ: IONS) has decreased by -1.76 when compared to last closing price of 36.84. Despite this, the company has experienced a 3.08% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-11 that CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. “Dosing the first person with Angelman syndrome in our pivota.
IONS’s Market Performance
IONS’s stock has risen by 3.08% in the past week, with a monthly rise of 7.93% and a quarterly rise of 8.32%. The volatility ratio for the week is 2.46% while the volatility levels for the last 30 days are 1.74% for Ionis Pharmaceuticals Inc The simple moving average for the past 20 days is 5.76% for IONS’s stock, with a 2.18% simple moving average for the past 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with H.C. Wainwright repeating the rating for IONS by listing it as a “Buy.” The predicted price for IONS in the upcoming period, according to H.C. Wainwright is $45 based on the research report published on April 07, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see IONS reach a price target of $39. The rating they have provided for IONS stocks is “Neutral” according to the report published on March 31st, 2025.
BMO Capital Markets gave a rating of “Market Perform” to IONS, setting the target price at $60 in the report published on August 02nd of the previous year.
IONS Trading at 14.85% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.86% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Hayden Michael R, who purchase 15,000 shares at the price of $31.86 back on May 01 ’25. After this action, Hayden Michael R now owns 50,219 shares of Ionis Pharmaceuticals Inc, valued at $477,900 using the latest closing price.
Birchler Brian, the EVP, Corp and Development Ops of Ionis Pharmaceuticals Inc, sale 680 shares at $28.37 during a trade that took place back on Apr 16 ’25, which means that Birchler Brian is holding 56,660 shares at $19,292 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.98 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.64. The total capital return value is set at -0.18. Equity return is now at value -118.53, with -16.41 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at 2.96. The interest coverage ratio of the stock is -5.26.
Currently, EBITDA for the company is -475.08 million with net debt to EBITDA at -2.97. When we switch over and look at the enterprise to sales, we see a ratio of 9.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.66.
Conclusion
To sum up, Ionis Pharmaceuticals Inc (IONS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
